March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Long-term Studies On The Anti-VEGF Treatment Success In Age-related Macular Degeneration (amd)
Barbara Kloeckener-Gruissem; Moreno Menghini; Florian Sutter; Johannes Fleischhauer; Malaika Kurz-Levin; Wolfgang Berger; Daniel Barthelmes
Author Affiliations & Notes
  • Barbara Kloeckener-Gruissem
    Institute of Medical Molecular Genetics, University of Zurich, Schwerzenbach, Switzerland
    Department of Biology, ETHZ, Zurich, Switzerland
  • Moreno Menghini
    Department of Ophthalmology, University Hospital of Zurich, Zurich, Switzerland
  • Florian Sutter
    Department of Ophthalmology, University Hospital of Zurich, Zurich, Switzerland
  • Johannes Fleischhauer
    Department of Ophthalmology, University Hospital of Zurich, Zurich, Switzerland
  • Malaika Kurz-Levin
    Department of Ophthalmology, University Hospital of Zurich, Zurich, Switzerland
  • Wolfgang Berger
    Institute of Medical Molecular Genetics, University of Zurich, Schwerzenbach, Switzerland
    Center for Integrative Human Physiology (ZIHP), University of Zurich, Zurich, Switzerland
  • Daniel Barthelmes
    Department of Ophthalmology, University Hospital of Zurich, Zurich, Switzerland
    Save Sight Institute, University of Sydney, Sydney, Australia
  • Footnotes
    Commercial Relationships  Barbara Kloeckener-Gruissem, None; Moreno Menghini, None; Florian Sutter, None; Johannes Fleischhauer, None; Malaika Kurz-Levin, None; Wolfgang Berger, None; Daniel Barthelmes, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 5168. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Long-term Studies On The Anti-VEGF Treatment Success In Age-related Macular Degeneration (amd)
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      Barbara Kloeckener-Gruissem, Moreno Menghini, Florian Sutter, Johannes Fleischhauer, Malaika Kurz-Levin, Wolfgang Berger, Daniel Barthelmes; Long-term Studies On The Anti-VEGF Treatment Success In Age-related Macular Degeneration (amd). Invest. Ophthalmol. Vis. Sci. 2012;53(14):5168.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose: : The optimal treatment strategy of patients with neovascular age-related macular degeneration (AMD) is currently under debate. Widely applied is a so-called loading phase with initially three consecutive intravitreal anti-VEGF injections. Recently it was demonstrated that genetic factors could influence the visual acuity (VA) outcome. Furthermore, studies have suggested that patients carrying specific genetic variations may require a higher number of injections. The aim of this study was to assess the respective impact of genetic factors and treatment strategies on the VA outcome.

Methods: : Retrospective analysis of the clinical data of neovascular AMD patients treated with intravitreal ranibizumab during a follow up period of 24 months. Assessment of course of VA was performed. The effect of a loading phase, the influence of an initial gain in visual acuity with respect to the extended treatment period of 12 and 24 months as well as the effect of a genetic component on these conditions were analyzed. Genotypes for SNP rs1061170 at CFH were identified and their frequencies were compared between different groups.

Results: : A total of 238 eyes were included in the final analyses. 62 eyes had received a loading phase. The VA outcome for eyes, which received loading phase and those that did not, were similar. Furthermore, eyes showing an initial gain in VA tended to retain the improvement during the study period. The homozygous CC genotype of SNP rs1061170 at CFH was more frequently found in patients belonging to the group of poor responders (75 percentile) after 24 months (OR=3.57784; CI 1.22180to 10.4771; P=0.0200), as previously reported for 12 months follow-up.

Conclusions: : Loading phase does not seem to influence the long-term outcome of visual acuity. The initial gain is a predictive factor for the long-term course of VA. So far, genetic variations as opposed to various treatment schedules are the only factors found to influence the VA outcome.

Keywords: age-related macular degeneration • visual acuity • genetics 
© 2012, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2024 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept